Advertisement
U.S. markets closed

BioCardia, Inc. (BCDA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4070-0.0121 (-2.89%)
At close: 04:00PM EDT
0.4147 +0.01 (+1.89%)
After hours: 07:34PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close0.4191
Open0.3900
Bid0.2863 x 200
Ask0.5070 x 200
Day's Range0.3900 - 0.4150
52 Week Range0.3600 - 2.9200
Volume285,326
Avg. Volume391,468
Market Cap10.682M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.6100
Earnings DateMay 08, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BCDA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BioCardia, Inc.
    Daily – Vickers Top Buyers & Sellers for 04/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • Thomson Reuters StreetEvents

    Q4 2023 BioCardia Inc Earnings Call

    Q4 2023 BioCardia Inc Earnings Call

  • GlobeNewswire

    BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

    SUNNYVALE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2023 and filed its annual report on Form 10-K with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights with call details below. “Heart f

  • GlobeNewswire

    BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024

    SUNNYVALE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2023 and provide a corporate update by conference call on Wednesday, March 27, 2024 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session. Participants can register for th